Abstract 46P
Background
Lenvatinib has been identified as a multikinase inhibitor with the effect of inhibiting angiogenesis for advanced ICC. This study aimed to compare the efficacy and safety of GEMOX and PD-1 inhibitors combined with or without lenvatinib as first-line therapy for advanced ICC.
Methods
Eligible participants with treatment naive and diagnosis of unresectable advanced ICC were assigned to G-P-L group: gemcitabine (1000 mg/m2on days 1 and 8 every 3 weeks), oxaliplatin (85 mg/m2on day 1 every 3 weeks), PD-1 inhibitors and lenvatinib (12 mg for weight ≥ 60 kg or 8 mg for weight < 60 kg, once daily), and G-P group: gemcitabine, oxaliplatin and PD-1 inhibitors. The primary endpoints was to assess objective response rate (ORR) evaluated with mRECIST 1.1 and adverse events (AEs). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Genetic mutation biomarkers for lenvatinib were explored using WES.
Results
77 patients were enrolled and divided into G-P-L group (n=38) and G-P group (n=39). The median follow-up time was 23 months. The median PFS were 13 months in the G-P-L group and 7.9 months in the G-P group (hazard ratio[HR]: 0.38, 95% CI: 0.20–0.71, P=0.007). The median OS were 18.5 months in the G-P-L group and 14.6 months in the G-P group (P=0.19). No significant differences of grade ≥ 3 AEs were found between the G-P-L group and the G-P group (68.4% and 64.1%). ORR, DCR were 39.5% and 89.5% in the G-P-L group versus 33.3% and 76.9% in the G-P group, respectively. Multivariate Cox regression analysis indicated that with or without Lenvatinib combination was the independent risk factor of PFS in the entire group (P=0.002). Keap-1 gene mutation was found with significant difference in PR group comparing with SD and PD group in the G-P-L group (P=0.003).
Conclusions
GEMOX combined with PD-1 inhibitor and lenvatinib indicated the feasibility as first-line therapy for advanced ICC with Keap-1 gene mutation. Multi-center with large scale of cases study were needed for further exploration.
Clinical trial identification
NCT05215665.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
252P - Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy
Presenter: Katarzyna Pogoda
Session: Poster session 13
253P - Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy
Presenter: Marcela Carausu
Session: Poster session 13
254P - IHC and GEX biomarkers and their prognostic and treatment predictive role in the neoadjuvant treatment of breast cancer
Presenter: Hani Saghir
Session: Poster session 13
255P - Predicting early recurrence in breast cancer patients undergoing neo-adjuvant chemotherapy through MRI-radiomics analysis
Presenter: Anna D'Angelo
Session: Poster session 13
256P - Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
Presenter: Shuling Zhou
Session: Poster session 13
257P - Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
Presenter: Andrea Joaquin Garcia
Session: Poster session 13
258P - Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)
Presenter: Coralia Bueno Muiño
Session: Poster session 13
1954P - 5-methylthioadenosine phosphorylase (MTAP) loss in clinically advanced uveal melanoma (CAUM): A comprehensive genomic profiling (CGP) study
Presenter: Nimisha Srivastava
Session: Poster session 13
1955P - Glycan-programmed T cell immunity: Effective adoptive T cell transfer in a CRC preclinical model
Presenter: Yong Miao
Session: Poster session 13
1956P - Integrative analysis of 26848 human transcriptomes reveals cancer-defining transcriptional architecture at the isoform resolution
Presenter: Junghoon Shin
Session: Poster session 13